Thank you to our speakers, sponsors and delegates who joined us in 2026 for the summit! If you are interested in the 2027 event please get in touch at info@hansonwade.com.

Accelerating the Discovery of Molecular Glues Against Novel Undruggable Targets

Enabling Rapid Target Selection, Discovery & Rational Design of Degrading & Non-Degrading Molecular Glue to Develop Potent, Selective & Safer Cures for Cancer & Beyond

Molecular glues were leading the charge in the race to drug the previously undruggable, and 2025/2026 saw continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brought top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting provided actionable strategies to accelerate the development of safer, more selective candidates toward the clinic. 

Attendees explored cutting-edge topics including target selection principles, rational design frameworks, sensitive assay technologies, lead optimization, and AI/ML approaches for rapid and reliable glue discovery. Attendees delved into emerging frontiers in non-degrading molecular glues and approaches outside oncology to unlock new therapeutic modalities, expand glues to novel indications, and stay ahead of the curve in the glues space. 

If you’re looking to lead the way in the molecular glue space, connect with the brightest minds, and gain practical insights to drive programs forward – 2027 your chance to solve the field’s unique challenges and shape the next wave of innovative therapies. 

This meeting serves as a catalyst for innovation bridging basic discovery and translation. Exploring new rational design frameworks and sensitive detection methods will advance our ability to systematically uncover and exploit molecular glue mechanisms

Mikolaj Slabicki, Principal Investigator, Massachusetts General Hospital

Massachusetts General Hospital

This meeting offers an opportunity to hear about a wide variety of strategies being employed to identify molecular glues and to connect with individuals who are bringing a high level of innovative problem solving to these challenges

Patrick Arsenault, Senior Director, Lead Discovery, Triana Biomedicines

Triana Biomedicines logo

As a scientist and entrepreneur, I see tremendous value in participating in the 4th Molecular Glue Drug Development meeting. It brings together leaders across industry and academia to share insights, challenges, and progress in a rapidly evolving field

Anita Bellail, Chief Executive Officer, HB Therapeutics

Therapeutics logo

Explore the 2026 Full Event Guide

  • 20+ Leading Molecular Glue Experts Presenting
  • 3 Days of Data-Driven Glues Content
  • Exclusive Networking & Partnership Opportunities
  • 2 Interactive & Deep-Diving Workshops
  • The Definitive Meeting for Molecular Glue Drug Discovery & Development
ee7 brochure image

70+

Attendees

20+

Speakers

17+

Data-Driven Presentations

7+

Hours of In-Person Networking

2

Interactive Workshops

1

Scientific Poster Session

Attending Companies Included

Biogen Logo
Takeda Logo
Rapafusyn logo
Plexium logo
Halda Therapeutics logo
Lyterian Therapeutics Logo
Aevis Bio logo
Novartis logo
Triana Biomedicines logo
Woman speaking to a crowd
Explore the Agenda

Hear the latest trends in molecular glue development and gain exclusive insights during our packed agenda, interactive roundtables and deep dive workshops.

Two men shaking hands
Partner With Us

Position yourself as a leading solution provider within the molecular glue space to ensure your brand is at the heart of biopharma deals.  

Audience watching speaker
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees developing molecular glues, and make critical connections during our dedicated networking sessions.